SCHEMBL4961817

SCHEMBL4961817

O=Cc1nn[nH]c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
GAA P10253 2/20 0.38
HSD17B10 Q99714 2/20 0.38
PLA2G10 O15496 1/20 0.38
BTK Q06187 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.35
MAPK1 P28482 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP1A2 P05177 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GSR P00390 1/20 0.34
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
TP53 P04637 1/20 0.33
CYP2A6 P11509 1/20 0.33
DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071799 0.81 MAPK14 (0.39) NPC1RAB9AKDM4EALDH1A1
SCHEMBL4963651 0.80 NOTUM (0.41) KDM4ECYP3A4
SCHEMBL30839322 0.75 GAA (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL4961979 0.75 NOTUM (0.38) KDM4EALDH1A1MAPK1NPSR1MAPT
SCHEMBL28351207 0.73 KDM4E (0.34) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL453506 0.71 KDM4E (0.48) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL27320867 0.70 HPGD (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL6846757 0.70 KDM4E (0.42) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL9984526 0.69 KDM4E (0.38) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL18039136 0.69 MAPK1 (0.52) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109232703-A Containing 16- (1 '-aromatic radical -1 ', 2 ', 3 '-triazoles) methylene-androstane -17- ketone derivatives 郑州大学 2019-01-18 CN disclosed
CN-101223143-A 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same WYETH CORP (US) 2008-07-16 CN disclosed
EP-1888529-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-02-20 EP disclosed
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-11-23 US disclosed
WO-2006124692-A2 3-CYANOQUINOLINE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264460-A1 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CSNK1A1L, CDKL1 NPC1 3109/4885RAB9A 3765/4885KDM4E 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.